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Introduction
The bone-targeted agents (BTAs), bisphosphonates (BPs) and 
denosumab, have several roles in breast cancer management in 
both the advanced metastatic setting and the early curative set-
ting. In the advanced setting, both BPs and denosumab reduce 
the skeletal complications associated with bone metastases. In 
the early setting, BPs and denosumab prevent the bone loss 
associated with curative systemic cancer therapies, with oral 
BPs and denosumab reducing bone loss and fracture rates in 
postmenopausal women, and zoledronic acid (ZA) being the 
most effective BP at reducing the high level of treatment-
induced bone loss in premenopausal women. More recently, the 
efficacy of BTAs to prevent breast cancer recurrence and 
improve survival, when given in early breast cancer, has been 
evaluated in large adjuvant breast cancer trials with evidence 
that BPs are effective at preventing recurrence in postmeno-
pausal women only, but denosumab does not appear to have a 
role in metastases prevention in either menopausal group. 
Despite decades of research with BTAs in breast cancer, several 
questions remain unanswered, including why there is a lack of 
benefit in disease recurrence prevention in premenopausal 
women with early breast cancer and how to optimally schedule 
BTAs in the metastatic setting. Some of these questions will be 
answered by ongoing clinical trials, but others will require a 
return to the preclinical setting.
Treatment of Breast Cancer Bone Metastases
Bisphosphonates have been in clinical use for breast cancer bone 
metastases for several decades. Bone, as the most common site 
of metastases from breast cancer, is adversely affected by 
tumour cells through initiation of the recognized ‘vicious cycle’ 
of bone metastases,1 leading to overactivity of bone forming 
osteoclasts, increased bone resorption, and the subsequent 
adverse clinical events in bone (termed skeletal-related events 
[SREs]; fracture, need for radiotherapy/surgery to bone and 
pain).
The concept that the osteoclast is the key bone cell to target 
to break this vicious cycle was taken forward in the clinical tri-
als of BPs in breast cancer. The intravenous (IV) BPs such as 
pamidronate and ZA demonstrated the highest efficacy in pre-
vention of SREs over the oral agents, and a phase III study 
comparing both drugs showed a significant reduction in SRE 
rates with ZA reducing SREs by 20%.2 Four BPs are currently 
approved for use in malignancy-associated metastatic bone dis-
ease in Europe and America, and include oral clodronate, oral 
or IV ibandronic acid, IV pamidronate, and ZA.3 While these 
drugs were effective at prevention of SREs, there was no con-
vincing evidence that they affected survival. A retrospective 
analysis of phase III trials of ZA showed that normalization of 
bone turnover at 3 months on ZA (as measured by N-telopeptide 
of type I collagen (NTX)), in patients with elevated bone 
resorption at baseline, correlated with improved overall sur-
vival4 with a reduction in risk of death in the breast cohort of 
patients of 48%. Whether this was due to prevention of frac-
ture and its associated morbidity and mortality, or an anti-can-
cer effect of ZA was not known.
Following incorporation of BPs into routine clinical practice 
for breast cancer bone metastases, questions arose regarding the 
optimal scheduling of these drugs. The half-life of ZA in bone is 
measurable in years with ongoing evidence of biological activity 
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for >3 years after a single infusion,5 suggesting the frequency of 
administration of ZA could be reduced. Studies evaluated the 
role of de-escalating scheduling frequency and showed that after 
a year of ZA administered every 4 weeks (Q4W), de-escalation 
to every 12 weeks (Q12W) could be done with no significant 
differences in SRE rate reported between the 2 schedules.6,7 The 
CALGB (Cancer and Leukemia Group B) protocol 70604 eval-
uated Q4W vs Q12W ZA for 2 years in patients with breast or 
prostate cancer or multiple myeloma (N = 1822) who had not 
received prior BTAs, with a primary endpoint of SRE rate at 
2 years. This study showed non-inferiority between the 2 sched-
ules (SRE rates: 29.5% Q4W vs 28.6% Q12W) after a median 
follow-up of 1.2 years.8 These studies suggest that de-escalation 
of BPs is possible, probably because of their long half-life in 
bone.
Denosumab In 2010, a phase III study of the new pan-osteo-
clast inhibitor, denosumab, was undertaken comparing SRE 
rates with the current gold standard treatment, ZA. 
Denosumab, while still targeting the osteoclast, has a different 
mechanism of action, acting as a monoclonal antibody, target-
ing RANKL and preventing RANK-mediated osteoclast acti-
vation. Its half-life in serum is 28 days, but it is not incorporated 
into bone. A large phase III study compared Q4W denosumab 
(120 mg subcutaneous) with Q4W ZA (4 mg IV), and showed 
that denosumab was superior to ZA in the prevention of first 
and subsequent on-study SREs (relative risk = 0.77; 95% con-
fidence interval [CI]: 0.66-0.89; P = .001 superiority) and had 
beneficial effects on pain. No survival differences were seen.9
Denosumab became the standard of care in many centres 
following this head-to-head study, but the optimal scheduling 
of denosumab still remains to be defined. Its lack of incorpora-
tion into bone makes the ability to de-escalate unknown at pre-
sent. In the osteoporosis setting, several case studies have 
reported that the resulting microarchitectural changes in tra-
becular bone on denosumab cessation have led to a rebound 
increase in vertebral fractures occurring within 2 to 10 months 
of stopping treatment.10 Prior vertebral fractures, before or 
during denosumab treatment, were the strongest predictors of 
off-treatment new fractures. This osteoporotic population will 
clearly have differences when compared with a breast cancer 
population; however, the prevalence of vertebral fractures in 
breast cancer patients with soft-tissue metastases and no skel-
etal metastases has been shown to be 20-fold higher than the 
normal population.11 Denosumab de-escalation studies are 
currently recruiting and results are awaited from the Swiss 
Group for Clinical Cancer Research (ClinicalTrials.gov identi-
fier: NCT02051218) who are evaluating initiation of deno-
sumab 120 mg Q4W for 3 doses followed by continuation at 
Q4W vs Q12W, with a primary endpoint of time to first on-
trial symptomatic skeletal event (SSE). In addition, the Ottawa 
Hospital Research Institute in Canada is evaluating BTAs 
(pamidronate, denosumab, or ZA) delivered Q4W vs Q12W 
in patients with breast or prostate cancer, with primary 
endpoints of Quality of Life, pain, and SREs, in patients due to 
commence or already receiving BTAs (REaCT-BTA trial, 
ClinicalTrials.gov Identifier: NCT02721433). It is hoped these 
trials will provide evidence to guide clinical de-escalation deci-
sions with denosumab.
Prevention of Cancer-Treatment-Induced Bone Loss
Bone loss as a result of curative breast cancer therapy is well 
recognized and is primarily a result of the effects of cancer 
therapies on oestrogen levels. Naturally occurring bone mineral 
density (BMD) loss in postmenopausal women is 1% per year12 
and increases to 2.6% with the use of aromatase inhibitors 
(AIs)13 with maximum effects seen in premenopausal patients 
receiving gonadotropin-releasing hormone (GnRh) agonists 
plus AI at 7% per year14 and those who experience primary 
ovarian failure as a result of chemotherapy at 7% per year.15 
The management of this accelerated bone loss requires lifestyle 
advice in addition to pharmacological intervention.16
Bisphosphonates
Bisphosphonates are generically available established treat-
ments used for the prevention of both benign and malignant 
bone loss. In premenopausal women with breast cancer only, 
the most potent BP, ZA, has been shown to reverse the signifi-
cant bone loss associated with ovarian suppression, but in post-
menopausal women, both IV infusion and oral BPs have shown 
efficacy in reversing AI-induced bone loss (reviewed in Hadji 
et al16). The majority of these studies have used the endpoint of 
BMD loss, but the more recently reported AZURE trial 
(ISRCTN79831382) evaluated the impact of adjuvant ZA on 
fractures in both premenopausal and postmenopausal women. 
The Adjuvant Zoledronic redUce REcurrence in early breast 
cancer (AZURE) trial is an academic, multi-centre, rand-
omized phase III study evaluating the addition of ZA 4 mg to 
standard therapy (neoadjuvant/adjuvant chemotherapy and/or 
endocrine therapy) for 5 years (administered IV every 3-4 weeks 
for 6 doses, then 3 monthly 8× and 6 monthly 5×) in patients 
with stage II/III early breast cancer. The 5-year fracture rate 
was reduced from 5.9% (95% CI: 4.8%-7.1%) (control) to 3.8% 
(95% CI: 2.9%-4.7%) with ZA. ZA significantly increased 
time to first fracture (hazard ratio [HR] = 0.69, 95% CI: 0.53-
0.90, P = .0053), but the majority of fracture prevention benefit 
occurred after a disease-free survival (DFS) event (HR = 0.3, 
95% CI: 0.17-0.53, P < .001) (see Figure 1).17 Fracture benefits 
from ZA were similar across menopausal subgroups. These 
data suggest that while ZA does decrease fracture incidence 
prior to disease recurrence, its effects are not as great as would 
have been predicted by the BMD studies.
Denosumab
The  Austrian Breast and Colorectal Cancer Study Group 
(ABSCG)-18 study randomized postmenopausal patients 
Ottewell and Wilson 3
with early hormone receptor positive breast cancer receiving 
AIs to receive either denosumab 60 mg or placebo adminis-
tered subcutaneously every 6 months. Denosumab halved 
fracture rates irrespective of baseline T-score,18 suggesting 
that the existing guidelines that recommend selecting of 
patients for treatment with osteoclast inhibitors on the basis 
of baseline BMD or loss of BMD over time19 may undertreat 
some patients at risk of fracture on adjuvant systemic therapy. 
The patient population in this study was low risk for recur-
rence with the majority having T1, node negative, grade 2, 
oestrogen receptor positive, and herceptin-negative tumours 
not requiring adjuvant chemotherapy.
Prevention of Formation of Metastases
Bisphosphonates
The emergence of data showing that BPs could improve sur-
vival and prevent recurrence, when used in the early breast can-
cer setting, came from the ABCSG-12 study which randomized 
premenopausal women rendered chemically postmenopausal 
with goserelin to tamoxifen or anastazole +/–ZA. There was a 
relative risk reduction of 29% for disease recurrence with ZA 
compared with endocrine only (HR = 0.71 95% CI: 0.55-0.92) 
with a significant overall survival benefit seen in women 
>40 years (HR = 0.57, 95% CI: 0.33-0.99, P = .042).20 
Following this, the AZURE study reported which used a more 
intensive schedule of ZA (detailed above) in premenopausal 
and postmenopausal women. Improvements in DFS with ZA 
were seen only in women who were >5 years postmenopausal 
at initiation of study with a relative risk reduction for 
recurrence of 25% (HR = 0.75, 95% CI: 0.59-0.96) and risk of 
death of 26% (HR = 0.74 95% CI: 0.55-0.98).21 These 2 studies 
taken together suggested that in patients with low levels of 
ovarian hormones, ZA was preventing disease recurrence. This 
led to a meta-analysis of individual patient data from 18 766 
patients treated with adjuvant BPs (predominantly ZA, clodro-
nate, and ibandronate) and demonstrated a highly significant 
reduction in breast cancer mortality (death rate 0.82; 95% CI: 
0.73-0.93) with BPs in postmenopausal women only. This was 
irrespective of tumour type, BP choice, and schedule. In the 
meta-analysis, the definition of menopausal status was a clini-
cal definition of premenopausal, perimenopausal, and post-
menopausal (natural or induced). If clinical menopausal status 
was unavailable, years of age was taken to define menopause 
(grouped as <45 [premenopausal], 45-54 [perimenopausal], 
⩾55 [postmenopausal]). In clinical practice, however, it is well 
recognized that menopause cannot be reliably assumed by 
age.22 If the clinical definition of menopause is not possible, the 
evaluation of a panel of female hormones at the start of BPs, 
including inhibin A, oestradiol, and follicle-stimulating hor-
mone, may assist patient selection for the treatment with adju-
vant BPs if these are in assay-specific postmenopausal range, as 
evidenced from the evaluation of these hormones in baseline 
serum samples of 865 patients randomized in the AZURE 
trial.23 In addition, this study showed that baseline oestradiol 
and follicle stimulating hormone (FSH) levels appeared to 
influence the pattern of disease recurrence, with a propensity 
for recurrences outside bone in women with postmenopausal 
levels irrespective of treatment received.23 This may indicate 
that the distribution of disseminated tumour cells (DTCs) at 
Figure 1. Interactions between menopausal status, treatment allocation, and frequency of clinical fractures. (A) Overall 5-year fracture rates in patients 
treated with ST (control) and ST plus ZOL according to menopausal status. Error bars are 95% CIs. Hazard ratios for time to irst fracture according to 
menopausal status are 0.45-0.88 for premenopausal, perimenopausal, and unknown menopausal groups, and 0.52-1.33 for >5 years postmenopausal 
group. (B) Two-year fracture rates post-DFS event in patients treated with standard therapy alone (control) and ST plus ZOL according to menopausal 
status. Error bars are 95% CIs. Hazard ratios for time to irst fracture post-DFS event according to menopausal status are 0.21-0.71 for premenopausal, 
perimenopausal, and unknown menopausal groups, and 0.06-0.75 for >5 years postmenopausal group. Reproduced with permission from Elsevier, 
Licence number 4381410096039.17 CIs indicate conidence intervals; DFS, disease-free survival; ST, standard therapy; ZA, zoledronic acid.
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the time of initiation of BPs could influence the disease-mod-
ifying efficacy of BPs within the bone microenvironment.
Following the meta-analysis, BPs have been incorporated 
into clinical care in Europe and America with relevant guide-
lines published to aid clinicians on how to select patients for 
treatment and suggested drug dosing schedules.16,24 The pub-
lished guidelines have recommended oral clodronate or IV ZA 
as choice of agent; however, ibandronate may be an additional 
choice of agent following results from the SWOG S0307 study 
of 6097 patients with stage I-III breast cancer randomized to 
receive 3 years of clodronate (1600 mg daily), ibandronate (50 mg 
orally daily), or ZA (4 mg IV monthly for 6 months, then 
3-monthly for 2.5 years), which showed no difference in 5-year 
DFS between the 3 arms.25 Recently, the phase III SUCCESS 
A trial compared 2 years of adjuvant ZA with 5 years, post-
chemotherapy in 3754 women with high-risk early breast cancer, 
and found no difference in DFS or overall survival between the 
2 groups, suggesting that the recommended 3 to 5 years in pub-
lished clinical guidelines could be reduced further.26
Denosumab
In the ABSCG-18 study of postmenopausal women, 
Gnant and colleagues reported fewer DFS events in 
patients treated with denosumab (n = 167) compared with 
placebo (n = 203), equivalent to an 18% reduced risk of 
recurrence at a median follow-up of 4 years;18 however, the 
study was unblinded and patients offered active treatment 
from 2016, so longer term survival data from this trial may 
not become available. The role of adjuvant denosumab was 
evaluated in the D-CARE study (NCT01077154) which 
recently reported at American Society of Clinical 
Oncology.27 In total, 4509 premenopausal and postmeno-
pausal patients with early breast cancer were randomized 
to receive standard (neo)adjuvant therapy +/–denosumab 
120 mg subcutaneous placebo monthly 6× then 3 monthly 
for up to 5 years. The primary endpoint was bone metasta-
sis free survival (BMFS), and no benefits for the addition 
of denosumab were seen in the overall population after a 
median follow-up of 67 months. Surprisingly, denosumab 
did not improve disease outcomes in the postmenopausal 
subset (n = 2149), which contradicts the results of the 
ABCSG-18 study. While denosumab does have a role in 
fracture prevention in postmenopausal low recurrence risk 
early breast cancer patients, it is now apparent that for 
those in whom risk of recurrence is greater, a BP would be 
the preferred choice of BTA.
Outstanding Questions – Can Preclinical Research 
Help?
In keeping with the clinical data, there have been a large num-
ber of preclinical studies describing anti-tumour effects of ZA 
alone or in combination with chemotherapy against breast 
cancer cells in the bone environment (see Table 1). Preclinical 
models have also shown increased efficacy of ZA against meta-
static outgrowth of dormant tumour cells in the skeleton of 
ovariectomized mice compared with sham-operated animals.36 
It was originally hypothesized that these anti-tumour effects 
were largely the result of ZA-induced osteoclast inhibition 
leading to a disruption of the vicious cycle. This hypothesis 
appeared to be supported by mouse experiments using the 
mouse monoclonal antibody to RANKL (fcOPG) that also 
showed reduced tumourigenesis in the bone of ovariectomized 
mice compared with sham-operated animals.45 In the clinic, 
however, administration of denosumab had no effect on metas-
tasis in premenopausal or postmenopausal women. It therefore 
appears that osteoclast activity is not the dominant driver of 
bone metastasis, and further research is required to establish 
the key mechanisms that promote this condition.
Evidence that adding ZA to chemotherapy inhibits growth 
of breast cancer cells outside of bone in mouse models (see 
Table 1) and reduces breast cancer recurrence in non-bone sites 
in postmenopausal women suggests that ZA is able to elicit 
anti-tumour effects outside of the bone environment. ZA is a 
potent inhibitor of the mevalonate pathway;44 this pathway is 
ubiquitous to all cell types and despite only being present in the 
circulation for ~4 h, adding ZA 24 h after doxorubicin has been 
shown to activate the mevalonate pathway and increase apop-
tosis in breast cancer cells in mouse models.33 It is possible that 
the differential anti-tumour effects of ZA in bone and in 
peripheral metastasis, according to menopausal status, are not 
due to reduced bone resorption but are driven by direct 
ZA-induced anti-tumour affects.
The differential effects of ZA in premenopausal and post-
menopausal women indicate a role for oestradiol in driving 
resistance to anti-tumour effects of ZA in peripheral metasta-
sis. Evidence from preclinical models has shown apposing roles 
for oestradiol; we and others have shown that low levels of 
oestradiol caused by ovariectomy promote outgrowth of 
tumour cells already disseminated in bone,45,46 whereas sup-
plementing mice with oestradiol enhances spontaneous metas-
tasis of oestrogen receptor positive (ER+ve cells) to bone.39 
Bone metastases were inhibited in both of these models by ZA 
in the absence of chemotherapy. Taking the clinical and pre-
clinical data together, data suggest that high oestradiol may 
attract tumour cells to bone and may influence their survival 
and dormancy in the bone microenvironment or cause them to 
disseminate to other organs.
The mechanisms of how oestradiol and ZA interact to affect 
tumour growth in bone and non-bone sites have not been iden-
tified. There is a suggestion from in vivo studies that low oestra-
diol levels may enhance ZA action through increasing 
interleukin (IL)-1 expression that ‘unmasks’ DTCs and makes 
them susceptible to death from high local concentrations of ZA 
in the bone microenvironment.47 Both oestradiol and ZA have 
profound effects on the immune system: oestradiol has 
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well-documented immunosuppressive effects via upregulation 
of programmed death ligand 1 (PD-L1).48 Recent data support 
that oestradiol also increases PD-L1 in breast cancer cells, and 
high PD-L1 expression levels in breast cancer inhibit T-cell 
anti-tumour responses.49 On the other hand, ZA acts as an 
immune modulator by significantly inhibiting expansion of 
regulatory T cells.50 It is, therefore, likely that oestradiol-
induced PD-L1 expression on tumour cells interferes with ZA 
activity in premenopausal women. Further research is underway 
in our laboratory that will establish whether targeting breast 
cancer cell PD-L1 with avelumab in combination with ZA has 
the potential to improve the anti-tumour efficacy of BPs in pre-
menopausal women.
In contrast to ZA, denosumab specifically targets RANKL 
leading to osteoclast apoptosis and reduced bone resorption. In 
addition, RANKL is a key mediator of progesterone action and 
Table 1. Summary table of preclinical studies showing anti-tumour efficacy of zoledronic acid alone or in combination with other therapeutic 
compounds.
CELL LInE/MODEL IMMUnE 
STATUS
MAjOR FInDInG REFEREnCES




Combining tegafur and uracil with zoledronic acid reduces growth 
of established bone metastases
Hiraga et al28
Zoledronic acid inhibits visceral metastasis Hiraga et al29




Administration of zoledronic acid 24 h after doxorubicin reduced 
bone metastases and increased survival
Ottewell et al30




Administration of zoledronic acid 24 h after doxorubicin reduced 
subcutaneous growth of breast cancer cells
Ottewell et al31
Sequential administration of doxorubicin 24 h before zoledronic 
acid reduced established bone metastases tumour via induction of 
the mevalonate pathway
Ottewell et al32
Sequential administration of doxorubicin to zoledronic acid 
increased subcutaneous tumour cell apoptosis via induction of the 
mevalonate pathway
Ottewell et al33
Triple negative PyMT 





Administration of zoledronic acid 24 h before doxorubicin delayed 
development of primary tumours and increased survival
Ottewell et al34




Combination of the cMET inhibitor tivantinib and zoledronic acid 
inhibited progression of established bone metastasis
Previdi et al35




Zoledronic acid reduced metastases from tumour cells 
disseminated in bone when used under postmenopausal 
conditions but not in the premenopausal bone environment
Ottewell et al36




Combining Camellia sinensis and metromic zoledronic acid 
reduces bone metastases from breast cancer cells disseminated in 
bone
Luo et al37




Combining Camellia sinensis and metromic zoledronic acid 
reduces primary tumour growth and metastasis to other organs
Luo et al38
Oestrogen receptor 




Zoledronic acid reduced spontaneous metastasis to mouse bone Holen et al39




Zoledronic acid alone or simultaneous administration of 
doxorubicin and zoledronic acid reduced primary tumour growth 
and delayed metastasis to other organs
Baklaushev 
et al40




Combining metronomic zoledronic acid with Coriolus versicolor 
reduces growth of breast cancer cells injected directly into mouse 
tibiae
Ko et al41
Combining zoledronic acid with halofuginone enhances the 







Zoledronic acid increased anti-tumour effects of fulvestrant in 
subcutaneous tumours
jia et al43
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is expressed by a number of different breast cancer cell lines. 
Systemic inhibition of RANKL in preclinical models blocked 
proliferation of the mammary epithelium and inhibited 
progesterone-driven tumorigenesis.51–53 These findings gave 
hope that denosumab would elicit a 2-pronged attack directly 
killing tumour cells and generating an unfavourable environ-
ment for bone metastases to establish. Unlike ZA, the effects of 
denosumab on anti-tumour immune cells are not reported, and 
there is limited data on the effects of this drug on different 
breast cancer subtypes. The failure of denosumab to elicit anti-
metastatic effects in women with breast cancer in the clinic 
highlights the need for further preclinical studies. Identifying 
why this denosumab appears to be a less effective anti-meta-
static therapy than initially hypothesized will allow research 
into novel methods of increasing its therapeutic efficacy.
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